SKP.L Share News (SKP)

Vectura-Skyepharma Merger Completed As Scheme Becomes Effective (ALLISS)

Skyepharma To Develop Product For US Opioid Market

Vectura Sees Narrowed Loss Ahead Of Skyepharma Deal Completion

Vectura Says Skyepharma Deal To Complete By June 10

Skyepharma Says Trading Good, Anticipates Full-Year Revenue Growth

Vectura, Skyepharma Merger Cleared By UK Competition Authority

AGM, EGM Calendar - Week Ahead

Skyepharma Says Flutiform Version Accepted For Europe Review

Vectura receives support from Skyepharma shareholder

(ShareCast News) - Vectura - which focuses on the development of pharmaceutical therapies for airways diseases - has received a letter of intent from a Skyepharma shareholder supporting the companies' proposed merger. Vectura said River and Mercantile Asset Management, which owns just under 4.8m Sky

Vectura Gets Support From Skyepharma Shareholder For Takeover (ALLISS)

UPDATE 1-Vectura to buy SkyePharma for $620 mln as UK biotech consolidates

* Agreed offer values SkyePharma at 410.15 pence a share * Combined group market value more than 1 billion pounds (Adds more on rationale for deal, comment from CEO) By Ben Hirschler LONDON, March 16 (Reuters) - Respiratory drug specialist Vectura has agreed to buy rival SkyeP

Skyepharma Agrees To Merge With Vectura As It Swings To Profit (ALLISS)

Skyepharma and Vectura agree merger; Skyepharma swings to profit

(ShareCast News) - Vectura and Skyepharma have reached an agreement on the terms of a recommended merger. Under the terms of the deal, Skyepharma shareholders will get 2.7977 new Vectura shares for each Skyepharma share. Based on Vectura's closing price of 146.60p on Tuesday, this values Skyepharma

Earnings, Trading Statements Calendar - Week Ahead

CORRECT (Jan 28): Skyepharma Signs Flutiform Deal With Mundipharma